Caplin Point Gets USFDA Nod

  Published 7 months ago

Caplin Point received USFDA approval for generic Milrinone injection, targeting acute decompensated heart failure treatment.

  • Approval covers two Milrinone infusion dosage forms, ensuring availability in safe, effective single-dose infusion bag packaging.
  • Milrinone Lactate Injection recorded $11 million in US sales for the 12 months ending July 2025.
  • Caplin Point expands presence in regulated US markets via subsidiaries Caplin Steriles and Caplin Steriles USA Inc.

You might like these

Vipul Organics Expands into Automotive Chemicals with New Compound

IMF Raises India's Growth, Risks Remain

Google Beam Challenges Zoom

GPPL Eyes Major Port Expansion

Trump's 2024 Financial Disclosures Reveal Crypto, Golf Income

Tata Steel Shares Slip Chrome Demand

Rossari Q1 Revenue Rises 11%

News that matters the most ⚡